Literature DB >> 30670538

Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details.

Vaishali Sanchorawala1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30670538      PMCID： PMC6341184          DOI： 10.1182/bloodadvances.2018021261

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  24 in total

1.  Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.

Authors:  Gregory P Kaufman; Stanley L Schrier; Richard A Lafayette; Sally Arai; Ronald M Witteles; Michaela Liedtke
Journal:  Blood       Date:  2017-06-14       Impact factor: 22.113

2.  Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.

Authors:  Parameswaran Hari; Huamao Mark Lin; Carl V Asche; Jinma Ren; Candice Yong; Katarina Luptakova; Douglas V Faller; Vaishali Sanchorawala
Journal:  Amyloid       Date:  2018-01-05       Impact factor: 7.141

Review 3.  What is new in diagnosis and management of light chain amyloidosis?

Authors:  Giovanni Palladini; Giampaolo Merlini
Journal:  Blood       Date:  2016-04-06       Impact factor: 22.113

4.  Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation.

Authors:  Sabrina Browning; Karen Quillen; J Mark Sloan; Gheorghe Doros; Shayna Sarosiek; Vaishali Sanchorawala
Journal:  Blood       Date:  2017-07-11       Impact factor: 22.113

5.  Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

Authors:  Vaishali Sanchorawala; Daniel G Wright; Michael Rosenzweig; Kathleen T Finn; Salli Fennessey; Jerome B Zeldis; Martha Skinner; David C Seldin
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

6.  Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.

Authors:  M I da Silva Filho; A Försti; N Weinhold; I Meziane; C Campo; S Huhn; J Nickel; P Hoffmann; M M Nöthen; K-H Jöckel; S Landi; J S Mitchell; D Johnson; G J Morgan; R Houlston; H Goldschmidt; A Jauch; P Milani; G Merlini; D Rowcieno; P Hawkins; U Hegenbart; G Palladini; A Wechalekar; S O Schönland; K Hemminki
Journal:  Leukemia       Date:  2016-12-27       Impact factor: 11.528

7.  Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

Authors:  Tilmann Bochtler; Ute Hegenbart; Christina Kunz; Martin Granzow; Axel Benner; Anja Seckinger; Christoph Kimmich; Hartmut Goldschmidt; Anthony D Ho; Dirk Hose; Anna Jauch; Stefan O Schönland
Journal:  J Clin Oncol       Date:  2015-03-16       Impact factor: 44.544

8.  Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.

Authors:  Giovanni Palladini; Paolo Milani; Andrea Foli; Marco Basset; Francesca Russo; Stefano Perlini; Giampaolo Merlini
Journal:  Blood       Date:  2017-11-03       Impact factor: 22.113

Review 9.  Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.

Authors:  G Merlini; I Lousada; Y Ando; A Dispenzieri; M A Gertz; M Grogan; M S Maurer; V Sanchorawala; A Wechalekar; G Palladini; R L Comenzo
Journal:  Leukemia       Date:  2016-07-15       Impact factor: 11.528

10.  A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time.

Authors:  Vaishali Sanchorawala; Kristen L McCausland; Michelle K White; Martha S Bayliss; Spencer D Guthrie; Stephen Lo; Martha Skinner
Journal:  Br J Haematol       Date:  2017-08-29       Impact factor: 6.998
View more
  5 in total

Review 1.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

2.  Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.

Authors:  Vaishali Sanchorawala; Shayna Sarosiek; Amanda Schulman; Meredith Mistark; Mary Ellen Migre; Ramon Cruz; J Mark Sloan; Dina Brauneis; Anthony C Shelton
Journal:  Blood       Date:  2020-04-30       Impact factor: 22.113

Review 3.  Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.

Authors:  Shayna Sarosiek; Vaishali Sanchorawala
Journal:  J Blood Med       Date:  2019-10-23

4.  Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis.

Authors:  Gareth J Morgan; Joel N Buxbaum; Jeffery W Kelly
Journal:  Hemato       Date:  2021-10-05

Review 5.  Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.

Authors:  Efstathios Kastritis; Ashutosh Wechalekar; Stefan Schönland; Vaishali Sanchorawala; Giampaolo Merlini; Giovanni Palladini; Monique Minnema; Murielle Roussel; Arnaud Jaccard; Ute Hegenbart; Shaji Kumar; Maria T Cibeira; Joan Blade; Meletios A Dimopoulos
Journal:  Br J Haematol       Date:  2020-07-04       Impact factor: 8.615
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.